Erik Harris

Insider Reports History

Entity
Individual
Location
60 Leveroni Court, Novato, CA
Signature
/s/ Sanjay Subramanian, as attorney-in-fact for Erik Harris
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Erik Harris:

Insider Reports Filed by Erik Harris

Symbol Company Period Transactions Value $ Form Type Date Filed Role
INZY Inozyme Pharma, Inc. Oct 3, 2024 1 $0 4 Oct 7, 2024 Director
INZY Inozyme Pharma, Inc. Oct 3, 2024 0 $0 3 Oct 7, 2024 Director
DNLI Denali Therapeutics Inc. May 31, 2024 2 $0 4 Jun 4, 2024 Director
RARE Ultragenyx Pharmaceutical Inc. Mar 1, 2024 4 -$256K 4 Mar 5, 2024 EVP & Chief Commercial Officer
RARE Ultragenyx Pharmaceutical Inc. Sep 5, 2023 1 -$228K 4 Sep 6, 2023 EVP & Chief Commercial Officer
RARE Ultragenyx Pharmaceutical Inc. Jun 19, 2023 1 -$14.7K 4 Jun 21, 2023 EVP & Chief Commercial Officer
DNLI Denali Therapeutics Inc. Jun 1, 2023 2 $0 4 Jun 5, 2023 Director
RARE Ultragenyx Pharmaceutical Inc. Mar 1, 2023 4 -$166K 4 Mar 3, 2023 EVP & Chief Commercial Officer
RARE Ultragenyx Pharmaceutical Inc. Jun 19, 2022 1 -$16.2K 4 Jun 22, 2022 EVP & Chief Commercial Officer
RARE Ultragenyx Pharmaceutical Inc. Mar 1, 2022 3 -$181K 4 Mar 3, 2022 EVP & Chief Commercial Officer
DNLI Denali Therapeutics Inc. Feb 7, 2022 0 $0 3/A Feb 14, 2022 Director
DNLI Denali Therapeutics Inc. Feb 3, 2022 2 $0 4 Feb 7, 2022 Director
DNLI Denali Therapeutics Inc. Feb 3, 2022 0 $0 3 Feb 7, 2022 Director
RARE Ultragenyx Pharmaceutical Inc. Oct 14, 2021 1 -$24.6K 4 Oct 18, 2021 EVP & Chief Commercial Officer
RARE Ultragenyx Pharmaceutical Inc. Jul 6, 2021 1 -$34.3K 4 Jul 8, 2021 EVP & Chief Commercial Officer
RARE Ultragenyx Pharmaceutical Inc. Jun 19, 2021 2 -$95.7K 4 Jun 23, 2021 EVP & Chief Commercial Officer
RARE Ultragenyx Pharmaceutical Inc. May 6, 2021 2 -$79.6K 4 May 10, 2021 EVP & Chief Commercial Officer